Cargando…
Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (E...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal of Therapeutics
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812425/ https://www.ncbi.nlm.nih.gov/pubmed/36608071 http://dx.doi.org/10.1097/MJT.0000000000001584 |
_version_ | 1784863723362451456 |
---|---|
author | Bryant, Andrew Johnson, Eugenie Grayling, Michael Hiu, Shaun Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj |
author_facet | Bryant, Andrew Johnson, Eugenie Grayling, Michael Hiu, Shaun Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj |
author_sort | Bryant, Andrew |
collection | PubMed |
description | We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. AREAS OF UNCERTAINTY: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. DATA SOURCES: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. THERAPEUTIC ADVANCES: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8–2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9–2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias. CONCLUSIONS: The results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area. |
format | Online Article Text |
id | pubmed-9812425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Journal of Therapeutics |
record_format | MEDLINE/PubMed |
spelling | pubmed-98124252023-01-12 Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis Bryant, Andrew Johnson, Eugenie Grayling, Michael Hiu, Shaun Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Am J Ther Therapeutic Advance We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. AREAS OF UNCERTAINTY: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. DATA SOURCES: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. THERAPEUTIC ADVANCES: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8–2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9–2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias. CONCLUSIONS: The results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area. American Journal of Therapeutics 2022-12-20 /pmc/articles/PMC9812425/ /pubmed/36608071 http://dx.doi.org/10.1097/MJT.0000000000001584 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Therapeutic Advance Bryant, Andrew Johnson, Eugenie Grayling, Michael Hiu, Shaun Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title | Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title_full | Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title_fullStr | Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title_full_unstemmed | Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title_short | Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis |
title_sort | residual disease threshold after primary surgical treatment for advanced epithelial ovarian cancer, part 1: a systematic review and network meta-analysis |
topic | Therapeutic Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812425/ https://www.ncbi.nlm.nih.gov/pubmed/36608071 http://dx.doi.org/10.1097/MJT.0000000000001584 |
work_keys_str_mv | AT bryantandrew residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT johnsoneugenie residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT graylingmichael residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT hiushaun residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT elattarahmed residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT gajjarketankumar residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT craigdawn residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT valeluke residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis AT naikraj residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis |